Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6820154 | 0.84 | ALDH1A1 (0.60) | ALDH1A1POLBTP53KMT2AMEN1 | |
| SCHEMBL28997154 | 0.83 | HDAC3 (0.57) | ALDH1A1POLBNAMPTTP53KMT2A | |
| SCHEMBL28997137 | 0.83 | POLB (0.62) | ALDH1A1POLBNAMPTTP53KMT2A | |
| SCHEMBL28997297 | 0.83 | NPC1 (0.61) | POLBNAMPTTP53KMT2AMEN1 | |
| SCHEMBL2577548 | 0.82 | NAMPT (0.62) | ALDH1A1NAMPTMAPTHPGDSMN1; SMN2 | |
| SCHEMBL12803387 | 0.82 | ALDH1A1 (0.53) | ALDH1A1POLBKMT2AMEN1MAPT | |
| SCHEMBL9109237 | 0.82 | CYP3A4 (0.59) | ALDH1A1NAMPTKMT2AMEN1MAPT | |
| SCHEMBL30226098 | 0.81 | MAPT (0.56) | ALDH1A1KMT2AMEN1MAPTHPGD | |
| SCHEMBL28997262 | 0.81 | MAPT (0.56) | ALDH1A1KMT2AMEN1MAPTHPGD | |
| SCHEMBL29005913 | 0.80 | HDAC3 (0.60) | POLBNAMPTTP53KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894323-A | Method for self-cyclizing cyanation of enaminoaniline compound | 湖北工业大学 | 2023-04-04 | — | — | CN | claimed |
| CN-121537383-A | Benzimidazole isoquinoline Synthesis method of ketonization reaction | 湖北工业大学 | 2026-02-17 | — | — | CN | disclosed |
| CN-116621723-B | Method for oxidizing non-activated end group olefin into secondary alcohol | 江苏科技大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-116621723-A | Method for oxidizing non-activated end group olefin into secondary alcohol | 江苏科技大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-115894323-A | Method for self-cyclizing cyanation of enaminoaniline compound | 湖北工业大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-109776378-A | Preparation method of polychlorinated methyl indoline without metal catalyst | 哈尔滨商业大学 | 2019-05-21 | — | — | CN | disclosed |
| US-7994172-B2 | [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism | EXELIXIS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | PDPK1, MTOR, RPS6KA2 | ALDH1A1 4083/4885POLB 3062/4885NAMPT 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.